CERO THERAPEUTICS HOLDINGS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.88 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2024-04-02
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-12-31 was $223.99K, a 76.24% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-09-30 was $165.11K, a 69.83% decline year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-06-30 was $1.13M, a 2609.49% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-03-31 was $364.06K, a 240.54% increase year-over-year.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.88M, a 14.85% increase from fiscal 2022.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.64M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 4 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 7 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2023-12-31 | $223.99K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | $389.10K derived: sum of 2 quarters · filed 2024-04-02 | $1.52M derived: sum of 3 quarters · filed 2024-04-02 | $1.88M 10-K · filed 2024-04-02 | ||
| 2023-09-30 | $165.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.29M derived: sum of 2 quarters · filed 2023-11-09 | $1.66M 10-Q · filed 2023-11-09 | $2.60M derived: sum of 4 quarters · filed 2024-04-02 | ||
| 2023-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.49M 10-Q · filed 2023-08-14 | $2.44M derived: sum of 3 quarters · filed 2024-04-02 | $2.98M derived: sum of 4 quarters · filed 2024-04-02 | ||
| 2023-03-31 | $364.06K 10-Q · filed 2023-05-12 | $1.31M derived: sum of 2 quarters · filed 2024-04-02 | $1.85M derived: sum of 3 quarters · filed 2024-04-02 | $1.90M derived: sum of 4 quarters · filed 2024-04-02 | ||
| 2022-12-31 | $942.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | $1.49M derived: sum of 2 quarters · filed 2024-04-02 | $1.53M derived: sum of 3 quarters · filed 2024-04-02 | $1.64M 10-K · filed 2024-04-02 | ||
| 2022-09-30 | $547.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $589.01K derived: sum of 2 quarters · filed 2023-11-09 | $695.92K 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $41.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $148.57K 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $106.91K 10-Q · filed 2023-05-12 | |||||
| 2021-12-31 | $14.43K 10-K · filed 2023-03-24 | |||||
| 2021-09-30 | $1.00K 10-Q · filed 2021-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |